Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201760 | 0.93 | PARP10 (0.43) | PARP15PARP10PARP2 | |
| SCHEMBL1201875 | 0.77 | NFE2L2 (0.50) | — | |
| SCHEMBL751432 | 0.75 | PARP15 (0.50) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL533162 | 0.73 | — | — | |
| SCHEMBL1976211 | 0.73 | — | — | |
| SCHEMBL2136269 | 0.73 | CHRNB2 (0.59) | PARP15PARP10PARP2CYP4F2CYP4A11 | |
| SCHEMBL4325641 | 0.72 | CHRNB2 (0.33) | PARP10 | |
| SCHEMBL29024848 | 0.71 | PARP15 (0.64) | PARP15PARP10PARP2TDP1SIGMAR1 | |
| SCHEMBL533380 | 0.70 | LTA4H (0.39) | — | |
| SCHEMBL1973942 | 0.70 | KDM1A (0.34) | PARP15PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016012384-A1 | TRIFLUORMETHYLOXAZINE AMIDINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-28 | — | — | WO | claimed |
| WO-2015132141-A1 | 1,3-OXAZINE-2-AMINE DERIVATIVES ACTING AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | claimed |
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | claimed |
| US-8389513-B2 | 2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | claimed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | claimed |
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | claimed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | claimed |
| WO-2016012384-A1 | TRIFLUORMETHYLOXAZINE AMIDINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-28 | — | — | WO | disclosed |
| WO-2015132141-A1 | 1,3-OXAZINE-2-AMINE DERIVATIVES ACTING AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| EP-2758393-A1 | N-(3-(2-AMINO-6,6-DIFLUORO-4,4A,5,6,7,7A-HEXAHYDRO-CYCLOPENTA[E][1,3]OXAZIN-4-YL)-PHENYL)-AMIDES AS BACE1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8754075-B2 | 1,3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| EP-2697208-A1 | 1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-02-19 | — | — | EP | disclosed |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | disclosed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188079-B2 | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011020806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | PARP15 1273/4885PARP10 3344/4885PARP2 1514/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | PARP15 1077/4885PARP10 3564/4885PARP2 1547/4885 |
| US-20120258962-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | PARP15 1629/4885PARP10 3062/4885PARP2 1053/4885 |
| US-20110046122-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | PARP15 1077/4885PARP10 3564/4885PARP2 1547/4885 |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | BACE2, BACE1, APP | PARP15 825/4885PARP10 2803/4885PARP2 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.